Predictive Oncology (NASDAQ:POAI) Shares Cross Below Two Hundred Day Moving Average – What’s Next?

Shares of Predictive Oncology Inc. (NASDAQ:POAI) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.08 and traded as low as $0.73. Predictive Oncology shares last traded at $0.79, with a volume of 76,521 shares.

Analysts Set New Price Targets

Separately, HC Wainwright assumed coverage on shares of Predictive Oncology in a research report on Monday, August 19th. They set a “buy” rating and a $3.00 price objective on the stock.

Predictive Oncology Trading Down 1.6 %

The stock has a market capitalization of $5.25 million, a PE ratio of -0.23 and a beta of 1.14. The stock has a 50 day moving average price of $0.76 and a 200-day moving average price of $1.08.

Predictive Oncology (NASDAQ:POAI) last announced its earnings results on Tuesday, August 13th. The medical instruments supplier reported ($0.68) earnings per share (EPS) for the quarter. Predictive Oncology had a negative return on equity of 200.06% and a negative net margin of 802.69%. The firm had revenue of $0.28 million during the quarter. Research analysts forecast that Predictive Oncology Inc. will post -2.03 earnings per share for the current year.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.